EMIF Deliverable 16.6: Guidance document for EMIF Scientific Publications

Executive summary

Executive Summary

Scientific publications, and specially papers, are considered to be one of the top outputs of research collaborative projects. A highly ambitious Project with an extended duration like EMIF needs to structure and plan its scientific communication activities to ensure full awareness and endorsement of the Consortium. The large size and diverse nature of the EMIF Consortium (e.g., pharmaceutical companies, SMEs, academia, etc.) provides a complex environment where special attention must be given to establishing internal pre-publication approval procedures.

The main audience to be targeted by the scientific dissemination activities is scientists from EMIF and neighbouring fields, who operate in a wide range of areas (computer science, bioinformatics, clinics, semantics, epidemiology, biomedicine, etc.). Specific results of more general interest can be disseminated to a wider audience, such as patient associations or the general public.

This guide provides a detailed overview on how the EMIF governance bodies interact and make decisions at different stages regarding the scientific pre-publication process. Given the size of the Consortium, special attention is paid into the description of the internal review process, both from the scientific content and conflict of interest point of view. Two separate procedures have been envisioned: 1) a full method, aimed at manuscripts that require an in-depth content review, and 2) a "fast-track", to be used in the case of short communications.

Special attention is put on the preservation of confidentiality, with the aim to ensure that both oral (seminars, posters, presentations at congresses, etc.) and written (conference abstracts, proceedings, or full-length manuscripts) scientific communications get all participants' approval.

Contacts

EMIF-PMO: Caroline Sage
csage@its.jnj.com

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant n° 115372).